Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Medtronic
Johnson and Johnson
Express Scripts

Last Updated: March 22, 2023

Heron Theraps Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for HERON THERAPS INC, and what generic alternatives to HERON THERAPS INC drugs are available?

HERON THERAPS INC has four approved drugs.

There are twenty-nine US patents protecting HERON THERAPS INC drugs.

There are ninety-two patent family members on HERON THERAPS INC drugs in twenty countries and seven supplementary protection certificates in four countries.

Summary for Heron Theraps Inc
International Patents:92
US Patents:29
Tradenames:4
Ingredients:3
NDAs:4

Drugs and US Patents for Heron Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-003 May 12, 2021 DISCN Yes No 9,744,163 See Plans and Pricing Y See Plans and Pricing
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-001 May 12, 2021 DISCN Yes No 10,098,957 See Plans and Pricing See Plans and Pricing
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-001 May 12, 2021 DISCN Yes No 10,980,886 See Plans and Pricing Y See Plans and Pricing
Heron Theraps Inc SUSTOL granisetron INJECTION, EXTENDED RELEASE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes 8,252,305 See Plans and Pricing See Plans and Pricing
Heron Theraps Inc CINVANTI aprepitant EMULSION;INTRAVENOUS 209296-001 Nov 9, 2017 RX Yes Yes 11,173,118 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Heron Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Heron Theraps Inc SUSTOL granisetron INJECTION, EXTENDED RELEASE;SUBCUTANEOUS 022445-001 Aug 9, 2016 6,613,355 See Plans and Pricing
Heron Theraps Inc SUSTOL granisetron INJECTION, EXTENDED RELEASE;SUBCUTANEOUS 022445-001 Aug 9, 2016 6,790,458 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Heron Theraps Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0734381 PA2004002 Lithuania See Plans and Pricing PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0748320 08C0019 France See Plans and Pricing PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381 3/2004 Austria See Plans and Pricing PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381 04C0010 France See Plans and Pricing PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
0748320 SPC/GB08/021 United Kingdom See Plans and Pricing PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
Dow
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.